Lancet HIV

Article	Citations
Optimising anal cancer screening through risk stratification	490
How do we prevent anal cancer in people living with HIV?	170
Evidence supports use of on-demand PrEP for HIV prevention	157
Lung cancer in people living with HIV	151
Transplant donation without discrimination	129
Argentina updates HIV laws	129
How much could long-acting PrEP cost in South Africa?	127
Controversial chronicler of LGBTQ rights	113
Correction to Lancet HIV 2022; 9: e791–800	108
Risk estimation in HIV reveals our usual blind spots	103
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	85
A moment of reckoning	83
Lenacapavir: an attractive option, but proceed with caution	77
Are we ready for long-acting HIV treatment for adolescents?	75
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	71
Steps toward quick and equitable roll-out of lenacapavir	71
The caveats of short-cycle antiretroviral therapy in adolescents living with HIV	68
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	66
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial	66
Growing old and well with HIV	64
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	62
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	58
Viral load data from South Africa builds confidence in U=U	58
Redefining care: injectable HIV treatment for adolescents	57
All roads lead to Westminster: the infected blood scandal	57

Making America unhealthy again	56
Recent gay Black history in the UK	54
Reducing HIV transmission in British Columbia, Canada	52
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa:	51
Standardisation of monitoring routines for new long-acting antiretrovirals in development	49
Unheard testimony	49
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	48
WHO recommends lenacapavir for HIV prevention	48
Sex as a biological variable in HIV-1 and schistosome co-infection	46
Preventing tuberculosis in advanced HIV disease	46
The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveys	46
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	43
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	43
Suicide prevention research is crucial to achieving health equity for people with HIV	39
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	39
Integration of sexual health and HIV services	39
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	37
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	36
Dolutegravir in neonates: finally we are getting there!	35
An eventful conference	34
Gains and gaps: addressing HIV in diverse sex worker groups	34
The impact of cuts in the US President's Emergency Plan for AIDS Relief funding for HIV pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	32
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	31
Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/	31
25 years of the Alliance for Public Health in Ukraine	31
HIV self-testing: from availability to strategic deployment	31
Eliminating HIV in the UK among men who have sex with men	31
Preventing sexually transmitted infections in the age of PrEP	31
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	30
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial	30
How can Africa sustain its HIV response amid US aid cuts?	30
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis	30
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	29
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	29
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	29
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	29
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	29
Reduction of HIV reservoir after stem cell transplantation	28
Advancing the prevention and treatment of HIV in children: priorities for research and development	28
Coffee with IAS President Beatriz Grinsztejn	27
Effects of self-testing on HIV outcomes in west Africa	27
Highlights from the 25th International AIDS Conference	27
Can treatment-as-prevention and PrEP reduce HIV incidence?	26
Implementation of PrEP in Latin America	26
Crucial need for improved pharmacovigilance in pregnancy	26
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	26
Second-line HIV treatments for adults in LMICs	25
Intersectional climate justice, health equity, and HIV	25
Optimised second-line regimens in the public health approach	25
MSM and HIV in the Middle East and north Africa	25

Correction to Lancet HIV 2025; 12: e691–700	25
Metabolic implications and safety of dolutegravir use in pregnancy	24
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	24
Addressing partner violence to end infant HIV infection	24
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	24
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	24
No woman left behind: achieving cervical cancer elimination among women living with HIV	24
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	23
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	23
Closing the gap to UNAIDS 95-95-95: Lesotho's success story	23
Complex response to HIV and tuberculosis in South Sudan	22
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	22
Cigarette smoking in PrEP recipients: a challenge and an opportunity	22
Metabolic syndrome and cardiovascular risk on INSTIs	21
Point-of-care testing to achieve paediatric 95-95-95 targets	20
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	20
Treatment of HIV and HBV coinfection	20
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	20
The HIV vaccine quest: ethical and implementation challenges	20
Need for clear inclusion criteria in reviews of antiretroviral treatments	20
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	20
A field of possibilities for paediatric HIV	19
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	19
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	19
Critical illness due to infection in people living with HIV	18
Activists step in to deliver PEP and PrEP in Mexico	18
HERO—providing support for those engaged in chemsex	18
Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study	18
Long-acting PrEP for adolescent girls and young women	18
HIV treatment in Russia on the brink of crisis	18
Consideration of brain health in ART interruption studies – Authors' reply	18
Unified health surveys for integrated health systems	18
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	17
Human impact of cuts to global aid in South Africa	17
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	17
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial	17
Combining long-acting bNAbs for durable HIV suppression	16
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	16
Improving outcomes for children in families with HIV	16
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	16
Realising long-acting ART as first-line treatment	16
Correction to Lancet HIV 2023; 10: e424–26	15
PEPFAR reauthorisation hangs in the balance	15
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	15
A career dedicated to public service	15
Correction to Lancet HIV 2025; 12: e473–84	15
Uptake of dapivirine vaginal ring and oral pre-exposure prophylaxis among women accessing HIV prevention services in South Africa: a cohort study	15
Expanding options of child-friendly, single-tablet regimens for young children with HIV	15
Tajikistan faces a crucial moment in HIV/AIDS response	15
Expanding PrEP treatment options with a potent anti-HIV antibody	15
HIV-related CNS infections: translating DREAMM into reality	14
Zvandiri—when medicines alone are not enough	14
Ending HIV in Chicago by 2030	14
Reimagining HIV prevention with artificial intelligence	13
Where does doravirine fit in current antiretroviral therapy?	13
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	13
Inherited fear: 40 years of HIV/AIDS in the UK	13
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	13
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	13
A research framework to support re-engagement and continuous engagement in HIV care	13
HIV viral suppression is key to healthy longevity	13
Enhancing HIV prevention through systematic community engagement, learning, and response	13
Putting people first in communication about HIV	12
Equitable access to PrEP is essential to reap its benefits	12
Long-acting PrEP: new opportunities with some drawbacks	12
Defining principles for a choice-based approach to HIV prevention	12
HIV prevention for young African women is about choice	12
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	12
Response to Thailand's commitment to support community-led HIV services	12
Screening for chlamydia and incidence of symptomatic infections	12
Home delivery of ART: could this be a reality in South Africa?	12
UK and US militaries update HIV policies	12
Correction to Lancet HIV 2025; 12: e712–21	12
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	12
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	11
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	11
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	11
What future for HIV vaccines?	11
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	11
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	11

Low-cost point-of-care urine test to enhance PrEP adherence	11
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-	11
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	11
Mexican perspective on the Mosaico HIV vaccine trial	11
Legislation threat to services for LGBTQ+ people in Georgia	11
Do we need routine integrase resistance testing before starting antiretroviral therapy?	10
Acceptability, feasibility, and effectiveness of caregiver-assisted HIV self-testing among children using an oral mucosal test in Uganda and Zambia: a prospective interventional study	10
Correction to Lancet HIV 2025; 12: e616–26	10
Dolutegravir dosing with rifampicin	10
Due south: navigating volatile health research landscapes	10
Elton John AIDS Foundation plugging gaps in HIV funding	10
Uganda integrates HIV care into general medical services	10
COP27 Climate Change Conference: urgent action needed for Africa and the world	10
Thailand's progress toward long-acting PrEP	10
CD4 cell counts at HIV diagnosis in the Eastern Mediterranean Region	10
Russia spiralling into an HIV crisis	10
The urgent need for opioid agonist treatment in Russia	10
Use of mobile phone data in HIV epidemic control	10
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	9
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial	9
Risk of donor-driven stigma in scale-up of long-acting PrEP	9
Advocacy and empowerment for people ageing with HIV	9
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	9
Using art to promote HIV prevention and highlight inequalities	9
Artificial intelligence in HIV research, policy, and clinical care	9
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	9
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	9
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	9
Understanding and managing disordered sleep in people with HIV	9
Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries	9
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of	9
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era	9